Abstract |
Imatinib is the single most effective agent in chronic myelogenous leukemia (CML) in blast phase (BP), inducing hematologic responses in 30 - 50% of patients. However, only a few of these are complete (CHR) and durable. Imatinib is synergistic with idarubicin and cytarabine. We administered imatinib 600 mg/day, cytarabine 10 mg/day subcutaneous, and idarubicin 12 mg/m2 intravenous every 14 days in 19 patients with CML in myeloid BP. Fourteen patients (74%) achieved a hematologic response: CHR in 9 (47%) (3 with complete and 1 with minor cytogenetic responses) and return to chronic phase (RTC) in 5 (26%). Median duration of response was 10 weeks (range, 2 - 89). Six patients received allogeneic stem cell transplantation: 4 CHR, 1 chronic phase and 1 BP. Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP.
|
Authors | Alfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Francis Giles, Deborah Thomas, William Wierda, Jorge Cortes |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 48
Issue 2
Pg. 283-9
(Feb 2007)
ISSN: 1042-8194 [Print] United States |
PMID | 17325887
(Publication Type: Journal Article)
|
Chemical References |
- Benzamides
- Piperazines
- Pyrimidines
- Cytarabine
- Imatinib Mesylate
- Idarubicin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Benzamides
- Blast Crisis
- Cytarabine
(administration & dosage)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Female
- Humans
- Idarubicin
(administration & dosage)
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, pathology)
- Male
- Middle Aged
- Pilot Projects
- Piperazines
(administration & dosage)
- Pyrimidines
(administration & dosage)
- Survival Rate
- Treatment Outcome
|